We seek to improve sexual health and wellness by providing convenient access to high-quality testing that prioritizes clinical integrity and consumer convenience. Our solutions are designed to break down screening barriers through discreet patient-tailored digital approaches that complement traditional brick-and-mortar care. In addition to our binx io molecular point-of-care (POC) diagnostic platform for chlamydia and gonorrhea, the two most notifiable STI conditions in the United States in 2019, we offer a comprehensive digital program that includes access to evidence-based testing, counseling, treatment, and follow up aimed at increasing testing and reducing infection spread.
binx io is a first-of-its-kind FDA-cleared, CLIA-waived, highly sensitive and specific, point-of-care (POC) diagnostic testing platform and is a rapid, qualitative, fully-automated test, designed to be easy to use, and intended for use in POC or clinical laboratory settings, providing the world's first sample-to-answer result in about 30 minutes for the detection of chlamydia (CT) and gonorrhea (NG)–the two most notifiable STI conditions in the United States as of 2019.
Reach out to us today at firstname.lastname@example.org learn more.
Address: 245 First St, Riverview II, 18th Floor, Cambridge, MA 02142
Support Inquiries: +1-844-692-4691 email@example.com
Corporate Inquiries: +1-646-847-8573 firstname.lastname@example.org